What is the effect of ACE inhibitors on bradykinins?

ACE inhibitors have a significant impact on bradykinin levels, leading to an increase in their concentration. These medications work by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in the renin-angiotensin-aldosterone system (RAAS). In addition to converting angiotensin I to angiotensin II, ACE is also responsible for the degradation of bradykinin, a peptide that functions as a vasodilator and has various roles in cardiovascular health.

When ACE is inhibited, the breakdown of bradykinin is reduced, resulting in higher levels of bradykinin in the bloodstream. This increase can contribute to the therapeutic effects of ACE inhibitors, such as lowering blood pressure and improving blood flow, as elevated bradykinin promotes vasodilation. Furthermore, the accumulation of bradykinin can lead to side effects such as cough, which is often associated with ACE inhibitor therapy.

In summary, the action of ACE inhibitors leads to an increase in bradykinin levels, which is an important mechanism that enhances their cardiovascular benefits.